Pieris Pharmaceuticals Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Pieris Pharmaceuticals's estimated revenue is currently $14.4M per year.
- Pieris Pharmaceuticals received $50.6M in venture funding in February 2018.
- Pieris Pharmaceuticals's estimated revenue per employee is $144150
- Pieris Pharmaceuticals's total funding is $16.5M.
- Pieris Pharmaceuticals has 100 Employees.
- Pieris Pharmaceuticals grew their employee count by 15% last year.
- Pieris Pharmaceuticals currently has 9 job openings.
|Simon Hsu||Executive Director, CMC|
|Tom Bures||VP Finance|
|Ahmed Mousa||Vice President, General Counsel & Corporate Secretary|
|Louis Matis||Chief Development Officer|
|Antoine Galou||Senior Director, Business Development and Portfolio Managament|
|Shane Olwill||VP/Head of Development/Immuno-Oncology|
|Mary Fitzgerald||VP Respiratory Medicine|
|Christine Rothe||VP/Head of Discovery & Alliance Management|
|Eckhard Niemeier||VP/Head of Business Development|
What Is Pieris Pharmaceuticals?
Pieris Pharmaceuticals (NASDAQ: PIRS) is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. Pieris is currently hiring in Boston and Freising, Germany. See here for our full list of job openings and information on applying: https://www.pieris.com/careerskeywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Pieris Pharmaceuticals News
BNP Paribas Arbitrage SA decreased its holdings in Pieris Pharmaceuticals Inc (NASDAQ:PIRS) by 41.3% during the 2nd quarter, according to ...
BOSTON, MA / ACCESSWIRE / September 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company ...
About Pieris Pharmaceuticals: Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to ...
Pieris Pharmaceuticals Funding
Pieris Pharmaceuticals Executive Hires
|2016-12-02||Claude Knopf||SVP/Chief Business Officer||Article|
|2017-10-13||Ingmar Bruns||Vice President of Clinical Development||Article|